MARKET

GENE

GENE

Genetic Technologies
NASDAQ
1.220
0.000
0.00%
Closed 17:21 10/04 EDT
OPEN
1.190
PREV CLOSE
1.220
HIGH
1.250
LOW
1.190
VOLUME
30.00K
TURNOVER
--
52 WEEK HIGH
3.230
52 WEEK LOW
0.9500
MARKET CAP
18.78M
P/E (TTM)
-3.7206
1D
5D
1M
3M
1Y
5Y
Australian stocks & ETFs rise after RBA’s smaller-than-expected interest rate hike
Stocks and exchange traded funds tied to the Australian market advanced in Tuesday's premarket trading in the U.S. The move came after the Reserve Bank of Australia raised interest rates by a lower-than-expected amount.The country's centra...
Seekingalpha · 22h ago
Journal Of Precision Medicine Publication Confirms GeneType Risk Test Outperforms Traditional Risk Assessments For Breast Cancer
MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and
Benzinga · 5d ago
BRIEF-Genetic Technologies Provides Update On U.S. Operations And Payer Engagement
BRIEF-Genetic Technologies Provides Update On U.S. Operations And Payer Engagement
Reuters · 09/02 13:35
Genetic Technologies Files For U.S. Patent Titled 'METHODS OF ASSESSING RISK OF DEVELOPING A SEVERE RESPONSE TO CORONAVIRUS INFECTION'
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220220246242%22.PGNR.&OS=DN/20220246242
Benzinga · 08/04 17:26
Gene achieves key milestones and growth
MELBOURNE, Australia, July 28, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease provides its cashflow results for the quarter ...
GlobeNewswire · 07/28 12:00
GeneType launches Multi-Test in Obstetrics clinics with more than 1,000 referring primary care physicians
MELBOURNE, Australia, July 18, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that we are partnerin...
GlobeNewswire · 07/18 12:00
Genetic Technologies Announced Partnership With Siles Health to Bring GeneType Risk Test to 9 Clinics
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that we are partnering with Melbourne based Siles Health, a leading Obstetrics...
Benzinga · 07/18 08:50
Genetic Technologies Unveils Partnership With Australia's Siles Health
MT Newswires · 07/18 07:00
More
About GENE
Genetic Technologies Limited (GTG) is an Australia-based diversified molecular diagnostics company. The Company is focused on the development and commercialization of genetic risk assessment technology. The Company is engaged in providing genomics-based tests in health, wellness and serious disease through its GeneType and EasyDNA brands. GTG is focused on developing an integrated predictive genetic testing and assessment tools enabling medical practitioners and their patients to proactively manage health. The Company’s geneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. The GeneType offers integrated risk testing for a range of serious conditions. GTG offers cancer predictive testing and assessment tools for physicians. Its Polygenic Risk Scores (PRS) platform offers integrated clinical and genetic risk delivering actionable outcomes from physicians and individuals.

Webull offers kinds of Genetic Technologies Limited (ADR) stock information, including NASDAQ:GENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GENE stock methods without spending real money on the virtual paper trading platform.